source
- Eli Lilly to merge U.S. and international units after exec retirement; Novartis records $1.9B impairment on failed Avidity drugEli Lilly announced that its U.S. and international divisions will be combined into a single unit called "Lilly Global Markets" after the retirement of long‑time executive Patrik Jonsson at the end…
- Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trialThe highest dose of retatrutide beat Ozempic on measures of blood sugar and weight loss, but was also associated with higher side effect rates and treatment discontinuations.BioPharma Dive · 15d ago↗ source
- Federal judge denies Novo's attempt to block Eli Lilly obesity drug ads